Summit Therapeutics PLC

Receive alerts
Market Cap:
£34.51 m
52 weeks high
52 weeks low

Viewing results 1-25 of 253


Summit presents DDS-04 data at antibiotic resistance conference

The drug developer presented in vivo proof of concept data for its antibiotics targeting Enterobacteriaceae in animal models of sepsis, pneumonia and UTI...

2 weeks, 3 days ago

Summit Therapeutics flags potential of new antibiotic to treat drug-resistant gonorrhoea

“The problem of gonorrhoea resistance is very concerning, and if nothing is done, physicians could see more and more cases of untreatable disease”...

on 07/17/2019

Latest data shows potential of Summit Therapeutics' DDS-04 antibiotic to treat pneumonia and sepsis

DDS-04 has now shown its potential to treat Enterobacteriaceae infections in all three key infection sites: urinary tract, bloodstream and lung...

on 07/09/2019

Summit Therapeutics in line to receive funding of up to US$64mln from US government

BARDA, part of the US Department of Health and Human Sciences, had previously agreed to provide Summit with up to US$62mln in funding to develop ridinilazole, but it has now upped this figure...

on 06/18/2019

Summit Therapeutics reduces first quarter losses

For the three months ended 30 April 2019, the antibiotic developer reported an operating loss of £4.8mln, down from £6.6mln a year ago...

on 06/12/2019

Summit Therapeutics well placed in the race to find next-generation antibiotic

Summit Therapeutics' potential breakthrough targets C.difficile...

on 04/16/2019

Summit Therapeutics soars as it hails potential of very early stage antibiotic

The treatment has been developed to tackle a gram-negative bacteria that is becoming resistant to current drugs ...

on 04/15/2019

Summit Therapeutics expands drug pipeline with antibiotics targeting deadly bacteria

The DDS-04 series provides us with a major opportunity to improve patient outcomes across several body sites where Enterobacteriaceae cause infection,” said Dr David Roblin, president of research and development of Summit ...

on 04/03/2019

Summit Therapeutics well backed for next phase of development

Phase III trials of its next-generation antibiotic began last month ...

on 03/27/2019

Summit Therapeutics shows off potential of Discuva platform at Berlin conference

The presentations are being made at Novel Antimicrobials and AMR Diagnostics 2019, which is being held in Berlin today and tomorrow...

on 03/14/2019

Summit Therapeutics shoots higher as data shows SMT-57 antibiotic potent against diverse, global gonorrhoeae strains

The group said SMT-571 was potent against Neisseria gonorrhoeae strains from actual patient cases, including numerous multi- and extensively-drug resistant strains...

on 02/25/2019

Bryan Garnier sets 155p fair value target on Summit Therapeutics, offering around 550% upside

The analysts said "we have established a fair value for Summit which we believe more accurately reflects its fundamental value than the current share price of 24p”...

on 02/19/2019

Summit Therapeutics says first patient dosed in global Phase 3 clinical trials for its precision oral antibiotic, ridinilazole

The Phase 3 programme comprises two global, randomised, double-blind, active-controlled clinical trials which will be run concurrently with each expected to enrol around 680 patients...

on 02/13/2019

Bob Duggan: Meet the US biotech billionaire taking a 49% stake in Summit

Duggan is said to be keen to finance the development of new antibiotics, with many viruses becoming increasingly resistant to the current cohort already out there...

on 12/17/2018

Summit funded through to 2020 thanks to US$25mln investment from US biotech billionaire

Summit has big plans for its flagship ridinilazole C. Diff treatment as well as its gonorrhoea and hospital superbug candidates this year, and it now has the funds to develop all of them as intended...

on 12/17/2018

US billionaire Robert Duggan to invest US$25mln into Summit Therapeutics

Duggan was the boss of Pharmacyclics and oversaw the company’s US$21bn sale to US pharma giant AbbVie back in 2015...

on 12/17/2018

Summit well-funded as it gears up for ridinilazole phase III trial early next year

Summit has £13.0mln in the bank, while its drugs have also been backed financially by external organisations keen to see new treatments come through...

on 12/11/2018

Summit Therapeutics presents data on gonorrhoea treatment at London event

Summit's gonorrhoea treatment SMT-571 is the focus of a presentation at the second SCI/RSC Symposium on Antimicrobial Drug Discovery...

on 11/12/2018

Summit Therapeutics to present successful studies of ridinilazole at IDWeek

Summit Therapeutics is on track to begin Phase III clinical trials of ridinilazole in the first quarter of next year...

on 10/03/2018

Summit identifies possible new ways to treat hospital-acquired superbugs

Using its Discuva platform, Summit has identified genes which are essential for pathogens like MRSA to survive, information which it will use to try to develop new drug candidates...

on 09/06/2018

Summit Therapeutics to kick off gonorrhoeae trial next year

Identified using the company’s Discuva Platform, the new drug is designed to exploit the N. gonorrhoeae target...

on 09/05/2018